Leukemia & Lymphoma

Article	Citations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study	84
Impact of SF3B1 mutation in myelofibrosis	46
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma	41
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia	33
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant	31
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review	25
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia	25
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis	24
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma	24
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	23
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination	22
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia	22
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma	21
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study	21
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia	20
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis	20
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes	19
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma	19
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management	19
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax	18
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma	18
Organ toxicities associated with chimeric antigen receptor T-cell therapy	18
Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models	18
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity	17
Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy	17

CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state	17
New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis	16
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports	16
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation	16
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini	16
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis	16
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)	15
Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust	15
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma	14
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma	14
Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)	14
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study	13
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans	13
Transplantation provides superior survival high risk myeloid malignancies in older patients	13
XX International workshop on chronic lymphocytic leukemia	13
Management of relapsed/refractory mantle cell lymphoma	13
NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma—opportunities for therapy	12
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia	12
Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study	12
Rare HNRNPH1::ERG rearrangement in a case of de novo pediatric AML and review of cases	12
Targeting mitochondrial metabolism in acute myeloid leukemia	12
Interferon maintenance for prevention of relapse in favorable risk AML?	12
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors	12
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy	12
Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients	12
Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study	12
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification	12
Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice	12
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma	12
Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?	12
Serum lipid trajectories in the years before a lymphoma diagnosis	12
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease	12
Trametinib enhances ATRA-induced differentiation in AML cells	11
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma	11
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic	11
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma	11
Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases	11
Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplanta	11
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS	11
A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma	11
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine	11
Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience	11
Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group	11
Infections in secondary immunodeficiency patients treated with Privigen®or Hizentra®: a retrospective US administrative claims study in patients with hematological malignancies	10
Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study	10
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome	10
Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia	10
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges	10
Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation	10
Impact of chronic graft- versus -host disease on non-relapse mortality and survival	10

Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma	10
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021	10
Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax	10
State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA)	10
Correction	10
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia	10
PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1 -like acute lymphoblastic leukaemia in Indian patients	10
Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study	10
Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma	10
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics	9
Two recurrent types of IGH ::5′ BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the	9
Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia	9
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy	9
The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma	9
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia	9
COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study	9
Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity	9
The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma	9
Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation	9
Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what’s next?	9
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas	9
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma	9
Prospects for liquid biopsy approaches in lymphomas	9
The diagnostic profile of rare acute myelomegakaryoblastic leukemia	9
Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy	9
Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway	9
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma	9
[ 211 At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies	9
Sun protection behaviors among adult survivors receiving hematopoietic cell transplantation: a cross-sectional survey of a single institution in Japan	9
A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse	9
Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment	9
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort stud	9
Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding	9
Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study	9
Prediction for sustained deep molecular response for treatment-free remission	9
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression	9
Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma	9
The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia	8
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir	8
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression	8
TP53 -altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs	8
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients	8
The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study	8
Familial aspects of multiple myeloma and Waldenström macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis	8
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen	8
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison	8
A single-center analysis of patients with extranodal marginal zone lymphoma of the breast	8
MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis	8
Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice	8
Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report	8
Challenging diagnosis of chronic myelomonocytic leukemia (CMML) in a patient with Takayasu arteritis: case report	8
Fatigue – a substantial problem in hematology, but what can be done?	8
Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab	8
The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?	8
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation	8
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia	8
Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study	8
CALR -mutated myeloproliferative neoplasms	8
Mitigating time toxicity in lymphoma and multiple myeloma	8
HHV8-Negative Effusion-Based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation	7
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation	7
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach	7
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia	7
Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study	7
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry	7
Anticipation in hematopoietic malignancies: biology, bias, or both?	7
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia	7
Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia	7
Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis	7
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group	7
Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis	7
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia	7
Emerging drug profile: JAK inhibitors	7
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma	7
Response to trametinib of two pediatric myeloid malignancies cases harboring RAS mutation and monosomy 7	7
Optimizing pegaspargase therapy in patients with hypersensitivity reactions	7
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation	7
Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin	7
Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia	7
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone	7

Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3	7
Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin	7
Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era	7
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients	7
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission	7
Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation	7
Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas	7
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases	7
Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma	7
Leukocytosis and MPNs: Where do we stand?	7
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin ( NPM1 ) gene mutation subtypes: a single-center experience and re	7
Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience	7
Successful treatment of acquired von Willebrand syndrome secondary to low-grade CLL with rituximab and venetoclax	7
Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old	6
Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis	6
Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment	6
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive	6
Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation	6
Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm	6
Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias	6
KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications	6
Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation	6
Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft	6
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing	6
COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies	6
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges	6
CD5- B-cell lymphocytic leukemia –a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus	6
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States	6
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor	6
Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10	6
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey	6
Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance	6
Normal and malignant cells are homogeneously distributed in the bone marrow of children	6
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma	6
Patterns of care and outcomes of early stage I–II Hodgkin lymphoma treated with or without radiation therapy	6
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma	6
Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive ch	6
Polymerase chain reaction in the diagnosis of invasive aspergillosis: approaches for appropriate use	6
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation	6
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function	6
A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3	6
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study	6
Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14	6
Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry	6
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia	6
Allogeneic transplant graft source – conditioning – GVHD prophylaxis: don’t mix and match!	6
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome	6
Promising activity of single agent nivolumab followed by low-dose whole brain radiotherapy in isolated central nervous system relapse of Hodgkin lymphoma	6
Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma	6
Correction	6
Correction	6
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the ‘RTL’ (regional Tuscan lymphoma network)	6
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma	6
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma	6
Treatment of relapsed and refractory Waldenstrom Macroglobulinemia	5
Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome	5
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment	5
The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing	5
The challenge of non-transplant eligible, newly diagnosed multiple myeloma	5
Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination	5
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy	5
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?	5
Innovative management of BK virus nephropathy post-HSCT: a case report and therapeutic insights	5
Bone primary, spindle cell variant of diffuse large B-cell lymphoma presenting in the femur from a Paget’s disease patient	5
Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab	5
Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C	5
Attempted desensitization to calaspargase pegol: a familiar approach to a new problem	5
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression	5
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma	5
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomono	5
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies	5
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults	5
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype	5
The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma	5
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data	5
Venetoclax promotes acute myeloid leukemia cells apoptosis by decreasing ac4C modification and mRNA expression of IMP3 through downregulating NAT10	5
Therapeutic approaches for the management of higher risk myelodysplastic syndromes	5
Validation of SAPS 3 for predicting in-hospital mortality in patients with haematological malignancy requiring ICU management	5
Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data	5
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)	5
Identification and genetic characterization of a NUP98-HHEX molecular rearrangement in a pediatric acute myeloid leukemia	5
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study	5
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review	5
Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma	5
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma	5
Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma	5
Response to ‘blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives’	5
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL	5
Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia	5
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant	5
Race (and ethnicity) matters in myelodysplastic syndromes	5
Be on guard: longer monitoring for very–late onset hepatitis B virus reactivation after chemo-immunotherapy?	5
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study	5
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia	5
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia	5